FILGRASTIM
Neuroepithelial Tumor
St. Jude Children's Research Hospitalprotein_peptidePhase 1Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Neuroepithelial Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TASADENOTUREV DNAtrix, Inc. | Phase 2 | B |
Pembrolizumab DNAtrix, Inc. | Phase 2 | B |
Interleukin-12 Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1/2 | CCC |
Sonidegib St. Jude Children's Research Hospital | Phase 1 | CC |
gsk1120212 St. Jude Children's Research Hospital | Phase 1 | CC |
View all 15 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →